Supernus Pharmaceuticals, Inc.
0LB2.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.46B
Close$
Share Statistics
| Market cap | $2.46 Billion |
|---|---|
| Enterprise Value | $2.32 Billion |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -10.66% |
|---|---|
| Return on Assets | -7.69% |
| Return on Invested Capital | -13.85% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.01 |
| Enterprise Value to EBIT | -15.5 |
| Enterprise Value to Net Income | -22 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Supernus Pharmaceuticals Inc
778 employees
CEO: Jack Khattar Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research, development, and market introduction of therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed medica...